Oncology News | pharmaphorum

News

Businessmen trading stocks online. Stock brokers looking at graphs, indexes and numbers on multiple computer screens. Colleagues in discussion in traders office. Business success concept.

TG Therapeutics raises funds for cancer combination drug

TG Therapeutics provided one of the highlights of the American Society of Hematology (ASH) conference earlier this month after lifting the lid on phase 3 data from its potential challenger

News

Daiichi Sankyo, AZ close on EU approval of Enhertu for breas...

Daiichi Sankyo and AstraZeneca could be just weeks away from an EU approval for their antib

News

Boehringer Ingelheim, Biberach, Germany, February 2007

Boehringer buys NBE for €1.18bn, adding cancer ADC expertise

Boehringer Ingelheim has expanded its oncology focus for the second time this week by buying Swiss biotech NBE-Therapeutics, adding an antibody-drug conjugate (ADC) platform led by a drug f

News

UK hospital deploys Microsoft AI to tackle cancer backlog

Addenbrooke’s Hospital in Cambridge will be the first in the world to use an artificial intelligence tool developed by Microsoft that promises to cut the time it takes to analyse computed t

News

FDA puts Bellicum's cancer cell therapy trial on hold

The FDA has placed a clinical hold on a phase 1/2 trial of Bellicum’s cancer cell therapy BPX-601, following a patient death.

News

ASH: Lilly builds case for its BTK drug LOXO-305 in lymphoma

Eli Lilly’s buyout of Loxo Oncology last year has already yielded one approved drug, and it now has a path to market for a second after BTK inhibitor LOXO-305 after reporting promising data

TG Therapeutics raises funds for cancer combination drug

Daiichi Sankyo, AZ close on EU approval of Enhertu for breas...

Boehringer buys NBE for €1.18bn, adding cancer ADC expertise

UK hospital deploys Microsoft AI to tackle cancer backlog

FDA puts Bellicum's cancer cell therapy trial on hold

ASH: Lilly builds case for its BTK drug LOXO-305 in lymphoma

FDA grants three priority vouchers to psychedelics

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks